Circulation. 2002;105:2099-2106
doi: 10.1161/01.CIR.0000014763.63528.9D
doi: 10.1161/01.CIR.0000014763.63528.9D
(Circulation. 2002;105:2099.)
© 2002 American Heart Association, Inc.
Clinical Cardiology: New Frontiers |
New Therapeutic Options in Congestive Heart Failure: Part I
From the Clinical Research Initiative in Heart Failure, University of Glasgow, Scotland (J.M.), and the Cardiovascular Division, Brigham and Women’s Hospital, Boston, Mass (M.A.P.).
Correspondence to Dr. John J.V. McMurray, Clinical Research Initiative in Heart Failure, University of Glasgow, Wolfson Building, Glasgow G12 8QQ, Scotland.
 |
Introduction |
|---|
The need for new treatments for congestive heart failure (CHF) is clear. Population morbidity and mortality, although they are improving, remain high.1,2 In this article, we review potential future therapies for CHF, building on our understanding of pathophysiological mechanisms and insights gained from previous studies of therapeutic interventions. The focus is on ambulatory CHF associated with left ventricular (LV) systolic dysfunction, although heart failure with preserved systolic function is also discussed. Given the broad scope of this review, individual areas can be addressed only briefly. The first part of this review deals with the pathophysiological basis of therapy and the use of neurohumoral antagonists in CHF with low LV ejection fraction (LVEF).
|
Pathophysiological Basis of Treatment |
|---|
Although the pathophysiology of CHF has recently been reviewed in detail, it is important to mention key concepts as the basis of therapy.3,4
Neurohumoral Pathways
Over the past 20 years, the "neurohumoral hypothesis" has evolved to focus less on the impact of these pathways on the blood vessels and kidneys and more on the heart (Figure 1, and see below).5 This in part reflects the benefit of ß-blockers and spironolactone, treatments that are not vasodilators.6–10 New peptides, such as the endothelins, and other mediators that are not conventional endocrine, autocrine, or paracrine factors, such as cytokines and free radicals, have also been postulated to play a role in CHF.11,12 These, in turn, are now thought to set into motion pathophysiological processes, such as apoptosis, that had not yet been recognized when the neurohumoral model was originally postulated (
This article has been cited by other articles:
 |
|
 |
|
  K. R. Sipido, A. Tedgui, S. D. Kristensen, G. Pasterkamp, H. Schunkert, M. Wehling, P. G. Steg, W. Eisert, F. Rademakers, B. Casadei, et al. Identifying needs and opportunities for advancing translational research in cardiovascular disease Cardiovasc Res, August 1, 2009; 83(3): 425 - 435. [Full Text] [PDF]
|
|
|
|
 |
|
 S. von Haehling, E. A. Jankowska, N. G. Morgenthaler, C. Vassanelli, L. Zanolla, P. Rozentryt, G. S. Filippatos, W. Doehner, F. Koehler, J. Papassotiriou, et al. Comparison of Midregional Pro-Atrial Natriuretic Peptide With N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Survival in Patients With Chronic Heart Failure J. Am. Coll. Cardiol., November 13, 2007; 50(20): 1973 - 1980. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Albouaini, M. Egred, A. Alahmar, and D. J. Wright Cardiopulmonary exercise testing and its application Postgrad. Med. J., November 1, 2007; 83(985): 675 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Albouaini, M Egred, A Alahmar, and D J Wright Cardiopulmonary exercise testing and its application Heart, October 1, 2007; 93(10): 1285 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zhou, P. D. Acton, and V. A. Ferrari Imaging Stem Cells Implanted in Infarcted Myocardium J. Am. Coll. Cardiol., November 21, 2006; 48(10): 2094 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. London Natriuretic Peptides and Cardiac Hypertrophy J. Am. Coll. Cardiol., August 1, 2006; 48(3): 506 - 507. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Schuchert and On behalf of the BISEX Investigators (Appendix A) Effects of bisoprolol treatment for chronic heart failure initiated and followed up by primary care physicians Eur J Heart Fail, June 1, 2005; 7(4): 604 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Davis, N. M. Albert, and J. B. Young Palliation of heart failure American Journal of Hospice and Palliative Medicine, May 1, 2005; 22(3): 211 - 222. [Abstract] [PDF]
|
|
|
|
|
|
S. Baudet Pathophysiology of heart failure: more bricks in the "crumbling sarcolemmal scaffolding" paradigm? Cardiovasc Res, February 1, 2005; 65(2): 299 - 301. [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Yan, R. T. Yan, and P. P. Liu Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials Ann Intern Med, January 18, 2005; 142(2): 132 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, S. Epperson, L. Makhsudova, B. Ito, J. Suarez, W. Dillmann, and F. Villarreal Functional effects of enhancing or silencing adenosine A2b receptors in cardiac fibroblasts Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2478 - H2486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y Sato, T Kita, Y Takatsu, and T Kimura Biochemical markers of myocyte injury in heart failure Heart, October 1, 2004; 90(10): 1110 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Corra, A. Mezzani, E. Bosimini, and P. Giannuzzi Cardiopulmonary Exercise Testing and Prognosis in Chronic Heart Failure*: A Prognosticating Algorithm for the Individual Patient Chest, September 1, 2004; 126(3): 942 - 950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ramani, M. Mathier, P. Wang, G. Gibson, S. Togel, J. Dawson, A. Bauer, S. Alber, S. C. Watkins, C. F. McTiernan, et al. Inhibition of tumor necrosis factor receptor-1-mediated pathways has beneficial effects in a murine model of postischemic remodeling Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1369 - H1377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Zile, C. F. Baicu, and W. H. Gaasch Diastolic Heart Failure -- Abnormalities in Active Relaxation and Passive Stiffness of the Left Ventricle N. Engl. J. Med., May 6, 2004; 350(19): 1953 - 1959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. MELO, A. S. PACHORI, D. KONG, M. GNECCHI, K. WANG, R. E. PRATT, and V. J. DZAU Gene and cell-based therapies for heart disease FASEB J, April 1, 2004; 18(6): 648 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Latini, S. Masson, I. Anand, M. Salio, A. Hester, D. Judd, S. Barlera, A. P Maggioni, G. Tognoni, J. N Cohn, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT Eur. Heart J., February 2, 2004; 25(4): 292 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. L. Schinkel, D. Poldermans, V. Rizzello, J.-L. J. Vanoverschelde, A. Elhendy, E. Boersma, J. R.T.C. Roelandt, and J. J. Bax Why do patients with ischemic cardiomyopathy and a substantial amount of viable myocardium not always recover in function after revascularization? J. Thorac. Cardiovasc. Surg., February 1, 2004; 127(2): 385 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Rossoni, B. Manfredi, V. Cavalca, R. Razzetti, S. Bongrani, G. L. Polvani, and F. Berti The Aminotetraline Derivative ({+/-})-(R,S)-5,6-Dihydroxy-2-methylamino-1,2,3,4-tetrahydro-naphthalene Hydrochloride (CHF-1024) Displays Cardioprotection in Postischemic Ventricular Dysfunction of the Rat Heart J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 633 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jessup and S. Brozena Heart Failure N. Engl. J. Med., May 15, 2003; 348(20): 2007 - 2018. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Feelisch Nitroxyl gets to the heart of the matter PNAS, April 29, 2003; 100(9): 4978 - 4980. [Full Text] [PDF]
|
|
|
|
|
|
M. Jessup Aldosterone Blockade and Heart Failure N. Engl. J. Med., April 3, 2003; 348(14): 1380 - 1382. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bartnik, K. Malmberg, and L. Ryden Diabetes and the heart: compromised myocardial function -- a common challenge Eur. Heart J. Suppl., January 1, 2003; 5(suppl_B): B33 - B41. [Abstract] [PDF]
|
|